Tags

Type your tag names separated by a space and hit enter

Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Int J Clin Pract. 2005 Jul; 59(7):817-22.IJ

Abstract

The cholinesterase inhibitors (ChE-Is)--rivastigmine, donepezil and galantamine--demonstrated efficacy in large, 6-month, double-blind, placebo-controlled trials, and are widely used for the symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD). Over the past few years, data have emerged, suggesting that these agents may have long-term benefits. These data have been summarized in this study, followed by an interpretation of clinical relevance. Data were identified by searches of Medline((R)) and references from relevant English-language articles. The search words 'Alzheimer', 'donepezil', 'rivastigmine', 'galantamine' and 'long term' were used. In addition, recent data presented at international congresses and/or provided by colleagues in this field of research were included in order to ensure maximum topicality. Data are available showing cognitive performance in patients remaining on rivastigmine for up to 5 years (n = 83), donepezil for up to 4.9 years (n = 18) and galantamine for up to 4 years (n = 185). Most of these data come from open-label studies and need to be interpreted with caution. The data appear to suggest that patients, caregivers and physicians will still see some decline on ChE-Is after a period of stabilization, but this may be slower and later than expected if the patients were left untreated. This applies across all domains of AD - not simply cognition - and function can be relatively preserved, even if cognitive scores are falling. Despite the limitations of current data, the information reviewed in this study may help practising doctors assess the long-term value of ChE-Is in this consistently progressive disease.

Authors+Show Affiliations

Kingshill Research Centre,Victoria Hospital, Okus Road, Swindon, UK. roger.bullock@kingshill-research.orgNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

15963209

Citation

Bullock, R, and A Dengiz. "Cognitive Performance in Patients With Alzheimer's Disease Receiving Cholinesterase Inhibitors for Up to 5 Years." International Journal of Clinical Practice, vol. 59, no. 7, 2005, pp. 817-22.
Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract. 2005;59(7):817-22.
Bullock, R., & Dengiz, A. (2005). Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. International Journal of Clinical Practice, 59(7), 817-22.
Bullock R, Dengiz A. Cognitive Performance in Patients With Alzheimer's Disease Receiving Cholinesterase Inhibitors for Up to 5 Years. Int J Clin Pract. 2005;59(7):817-22. PubMed PMID: 15963209.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. AU - Bullock,R, AU - Dengiz,A, PY - 2005/6/21/pubmed PY - 2005/10/4/medline PY - 2005/6/21/entrez SP - 817 EP - 22 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 59 IS - 7 N2 - The cholinesterase inhibitors (ChE-Is)--rivastigmine, donepezil and galantamine--demonstrated efficacy in large, 6-month, double-blind, placebo-controlled trials, and are widely used for the symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD). Over the past few years, data have emerged, suggesting that these agents may have long-term benefits. These data have been summarized in this study, followed by an interpretation of clinical relevance. Data were identified by searches of Medline((R)) and references from relevant English-language articles. The search words 'Alzheimer', 'donepezil', 'rivastigmine', 'galantamine' and 'long term' were used. In addition, recent data presented at international congresses and/or provided by colleagues in this field of research were included in order to ensure maximum topicality. Data are available showing cognitive performance in patients remaining on rivastigmine for up to 5 years (n = 83), donepezil for up to 4.9 years (n = 18) and galantamine for up to 4 years (n = 185). Most of these data come from open-label studies and need to be interpreted with caution. The data appear to suggest that patients, caregivers and physicians will still see some decline on ChE-Is after a period of stabilization, but this may be slower and later than expected if the patients were left untreated. This applies across all domains of AD - not simply cognition - and function can be relatively preserved, even if cognitive scores are falling. Despite the limitations of current data, the information reviewed in this study may help practising doctors assess the long-term value of ChE-Is in this consistently progressive disease. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/15963209/Cognitive_performance_in_patients_with_Alzheimer's_disease_receiving_cholinesterase_inhibitors_for_up_to_5_years_ L2 - https://doi.org/10.1111/j.1368-5031.2005.00562.x DB - PRIME DP - Unbound Medicine ER -